Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Atezolizumab + Platinum-Based Chemotherapy in Resectable NSCLC
2023-504209-35-00Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Atezolizumab + platinum-based chemotherapy (neoadjuvant) with Placebo + platinum-based chemotherapy (neoadjuvant control) (2 arms). Primary endpoint: IRF-assessed EFS. Started Apr 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-504209-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504209-35-00.